First-in-human study of CPL’116 – a dual JAK/ROCK inhibitor – in healthy subjects

BackgroundCPL’116 is a novel Janus kinase (JAK) and Rho-associated coiled-coil containing protein kinase (ROCK) dual inhibitor and a promising drug candidate for the treatment of inflammatory and fibrotic diseases. We conducted this first-in-human, Phase I clinical trial to evaluate the safety, phar...

Descripció completa

Dades bibliogràfiques

Autors principals:	Piotr J. Rudzki, Katarzyna Jarus-Dziedzic, Dorota Włodarczyk, Michał Kaza, Piotr Pankiewicz, Agnieszka Gierczak-Pachulska, Martyna Banach, Beata Zygmunt, Cezary Piwowarczyk, Paweł Żero, Daniel Rabczenko, Agnieszka Segiet-Święcicka, Maciej Wieczorek
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2025-04-01
Col·lecció:	Frontiers in Pharmacology
Matèries:	phase I (drug development) safety pharmacokinetics pharmacodynamics CPL’116 (previously CPL409116) Janus kinase (JAK)
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1583723/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!